What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Allogeneic human placental tissue particulate (PTP-001) is administered as a single intra-articular injection to the target knee after resuspension with saline.”In the company’s words, NCT05100225 on ClinicalTrials.gov
- Tested for
- Osteoarthritis, Knee
- Main trialPhase 2
- “Evaluation of safety, tolerability and efficacy of a single intra-articular (IA) injection of PTP-001, an allogeneic placental tissue particulate, in individuals with knee osteoarthritis (OA).”In the company’s words, NCT05100225 on ClinicalTrials.gov
Other drugs for Osteoarthritis, Knee
- JointstemR-Bio · Phase 3
- DiacereinTRB Chemedica · Phase 3
- Mesenchymal Stem CellsWuxi Cellular Biopharmaceutical Group Ltd. · Phase 3
- PTP-01Doron Therapeutics Inc. · Phase 3
- Sodium hyaluronateIBSA Institut Biochimique SA · Phase 3
- Pentosan Polysulfate SodiumParadigm Biopharmaceuticals Ltd. · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 31 Oct 2022 | Efficacy and Safety Trial of PTP-001 (MOTYS) for Symptomatic Knee Osteoarthritis | |
| Phase 1Unknown | Sep 2022 | Safety Study of PTP-001 for Treating Knee Osteoarthritis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026